Local Institution

Gothenburg SE-416 85

0 studies enrolling now · 33 studies all time

What they study most

Acute Coronary Syndrome (ACS), Acute Coronary Syndromes, Atrial Fibrillation, Blast Crisis, Breast Cancer, Cancer, Chronic Kidney Failure, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Congestive Heart Failure, Deep Vein Thrombosis, Deep-Vein Thrombosis

Studies at this site

• Pan Tumor Rollover Study — Recruiting now
• Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) — Completed
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) — Completed
• Effects of Abatacept in Patients With Early Rheumatoid Arthritis — Completed
• A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based — Completed
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
• A Phase III Study of Apixaban in Patients With Atrial Fibrillation — Completed
• Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant — Completed
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer — Stopped early
• A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma — Completed
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) — Completed
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis — Completed
• Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery — Completed
• Safety Study of Apixaban in Recent Acute Coronary Syndrome — Completed
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
• Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) — Completed
• PPAR - Combination With Metformin — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study — Completed